drugset / Trial / NCT06371157
A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma
RandomizedParallel-groupQuadruple-blindTreatment
Summary
A study to evaluate cadonilimab (AK104) + lenvatinib in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non-metastatic hepatocellular carcinoma
Timeline
- Start
- 2024-08-02
- Primary completion
- 2025-10-25
- Completion
- 2026-05-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | — | Intravenous |
| Subject | Lenvatinib | Small molecule | — | Oral |